Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortizatization of Intangibles: 2016-2025

Historic Amortizatization of Intangibles for Tg Therapeutics (TGTX) over the last 9 years, with Sep 2025 value amounting to $786,000.

  • Tg Therapeutics' Amortizatization of Intangibles fell 56.74% to $786,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 15.67%. This contributed to the annual value of $7.0 million for FY2024, which is 212.34% up from last year.
  • Tg Therapeutics' Amortizatization of Intangibles amounted to $786,000 in Q3 2025, which was down 38.74% from $1.3 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Amortizatization of Intangibles high stood at $2.5 million for Q4 2022, and its period low was -$409,000 during Q2 2021.
  • In the last 3 years, Tg Therapeutics' Amortizatization of Intangibles had a median value of $1.3 million in 2025 and averaged $1.1 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first soared by 4,271.70% in 2021, then slumped by 70.00% in 2023.
  • Tg Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $2.3 million in 2021, then climbed by 9.75% to $2.5 million in 2022, then slumped by 70.00% to $763,000 in 2023, then surged by 122.41% to $1.7 million in 2024, then tumbled by 56.74% to $786,000 in 2025.
  • Its last three reported values are $786,000 in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.